Cargando…

A strategy of local hydrogen capture and catalytic hydrogenation for enhanced therapy of chronic liver diseases

Background: Chronic liver diseases (CLD) frequently derive from hepatic steatosis, inflammation and fibrosis, and become a leading inducement of cirrhosis and hepatocarcinoma. Molecular hydrogen (H(2)) is an emerging wide-spectrum anti-inflammatory molecule which is able to improve hepatic inflammat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Geru, Liu, Feng, Jin, Zhaokui, Liu, Boyan, Wang, Hao, Li, Daosheng, Tang, Wei, Chen, Yuan, He, Qianjun, Qin, Shucun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196827/
https://www.ncbi.nlm.nih.gov/pubmed/37215568
http://dx.doi.org/10.7150/thno.80494
_version_ 1785044427931123712
author Tao, Geru
Liu, Feng
Jin, Zhaokui
Liu, Boyan
Wang, Hao
Li, Daosheng
Tang, Wei
Chen, Yuan
He, Qianjun
Qin, Shucun
author_facet Tao, Geru
Liu, Feng
Jin, Zhaokui
Liu, Boyan
Wang, Hao
Li, Daosheng
Tang, Wei
Chen, Yuan
He, Qianjun
Qin, Shucun
author_sort Tao, Geru
collection PubMed
description Background: Chronic liver diseases (CLD) frequently derive from hepatic steatosis, inflammation and fibrosis, and become a leading inducement of cirrhosis and hepatocarcinoma. Molecular hydrogen (H(2)) is an emerging wide-spectrum anti-inflammatory molecule which is able to improve hepatic inflammation and metabolic dysfunction, and holds obvious advantages in biosafety over traditional anti-CLD drugs, but existing H(2) administration routes cannot realize the liver-targeted high-dose delivery of H(2), severely limiting its anti-CLD efficacy. Method: In this work, a concept of local hydrogen capture and catalytic hydroxyl radical (·OH) hydrogenation is proposed for CLD treatment. The mild and moderate non-alcoholic steatohepatitis (NASH) model mice were intravenously injected with PdH nanoparticles firstly, and then daily inhaled 4% hydrogen gas for 3 h throughout the whole treatment period. After the end of treatment, glutathione (GSH) was intramuscularly injected every day to assist the Pd excretion. Results: In vitro and in vivo proof-of-concept experiments have confirmed that Pd nanoparticles can accumulate in liver in a targeted manner post intravenous injection, and play a dual role of hydrogen captor and ·OH filter to locally capture/store the liver-passing H(2) during daily hydrogen gas inhalation and rapidly catalyze the ·OH hydrogenation into H(2)O. The proposed therapy significantly improves the outcomes of hydrogen therapy in the prevention and treatment of NASH by exhibiting a wide range of bioactivity including the regulation of lipid metabolism and anti-inflammation. Pd can be mostly eliminated after the end of treatment under the assistance of GSH. Conclusion: Our study verified a catalytic strategy of combining PdH nanoparticles and hydrogen inhalation, which exhibited enhanced anti-inflammatory effect for CLD treatment. The proposed catalytic strategy will open a new window to realize safe and efficient CLD treatment.
format Online
Article
Text
id pubmed-10196827
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-101968272023-05-20 A strategy of local hydrogen capture and catalytic hydrogenation for enhanced therapy of chronic liver diseases Tao, Geru Liu, Feng Jin, Zhaokui Liu, Boyan Wang, Hao Li, Daosheng Tang, Wei Chen, Yuan He, Qianjun Qin, Shucun Theranostics Research Paper Background: Chronic liver diseases (CLD) frequently derive from hepatic steatosis, inflammation and fibrosis, and become a leading inducement of cirrhosis and hepatocarcinoma. Molecular hydrogen (H(2)) is an emerging wide-spectrum anti-inflammatory molecule which is able to improve hepatic inflammation and metabolic dysfunction, and holds obvious advantages in biosafety over traditional anti-CLD drugs, but existing H(2) administration routes cannot realize the liver-targeted high-dose delivery of H(2), severely limiting its anti-CLD efficacy. Method: In this work, a concept of local hydrogen capture and catalytic hydroxyl radical (·OH) hydrogenation is proposed for CLD treatment. The mild and moderate non-alcoholic steatohepatitis (NASH) model mice were intravenously injected with PdH nanoparticles firstly, and then daily inhaled 4% hydrogen gas for 3 h throughout the whole treatment period. After the end of treatment, glutathione (GSH) was intramuscularly injected every day to assist the Pd excretion. Results: In vitro and in vivo proof-of-concept experiments have confirmed that Pd nanoparticles can accumulate in liver in a targeted manner post intravenous injection, and play a dual role of hydrogen captor and ·OH filter to locally capture/store the liver-passing H(2) during daily hydrogen gas inhalation and rapidly catalyze the ·OH hydrogenation into H(2)O. The proposed therapy significantly improves the outcomes of hydrogen therapy in the prevention and treatment of NASH by exhibiting a wide range of bioactivity including the regulation of lipid metabolism and anti-inflammation. Pd can be mostly eliminated after the end of treatment under the assistance of GSH. Conclusion: Our study verified a catalytic strategy of combining PdH nanoparticles and hydrogen inhalation, which exhibited enhanced anti-inflammatory effect for CLD treatment. The proposed catalytic strategy will open a new window to realize safe and efficient CLD treatment. Ivyspring International Publisher 2023-04-23 /pmc/articles/PMC10196827/ /pubmed/37215568 http://dx.doi.org/10.7150/thno.80494 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Tao, Geru
Liu, Feng
Jin, Zhaokui
Liu, Boyan
Wang, Hao
Li, Daosheng
Tang, Wei
Chen, Yuan
He, Qianjun
Qin, Shucun
A strategy of local hydrogen capture and catalytic hydrogenation for enhanced therapy of chronic liver diseases
title A strategy of local hydrogen capture and catalytic hydrogenation for enhanced therapy of chronic liver diseases
title_full A strategy of local hydrogen capture and catalytic hydrogenation for enhanced therapy of chronic liver diseases
title_fullStr A strategy of local hydrogen capture and catalytic hydrogenation for enhanced therapy of chronic liver diseases
title_full_unstemmed A strategy of local hydrogen capture and catalytic hydrogenation for enhanced therapy of chronic liver diseases
title_short A strategy of local hydrogen capture and catalytic hydrogenation for enhanced therapy of chronic liver diseases
title_sort strategy of local hydrogen capture and catalytic hydrogenation for enhanced therapy of chronic liver diseases
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196827/
https://www.ncbi.nlm.nih.gov/pubmed/37215568
http://dx.doi.org/10.7150/thno.80494
work_keys_str_mv AT taogeru astrategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT liufeng astrategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT jinzhaokui astrategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT liuboyan astrategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT wanghao astrategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT lidaosheng astrategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT tangwei astrategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT chenyuan astrategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT heqianjun astrategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT qinshucun astrategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT taogeru strategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT liufeng strategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT jinzhaokui strategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT liuboyan strategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT wanghao strategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT lidaosheng strategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT tangwei strategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT chenyuan strategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT heqianjun strategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases
AT qinshucun strategyoflocalhydrogencaptureandcatalytichydrogenationforenhancedtherapyofchronicliverdiseases